Generic Rubraca Availability
Last updated on Sep 8, 2021.
Rubraca is a brand name of rucaparib, approved by the FDA in the following formulation(s):
RUBRACA (rucaparib camsylate - tablet;oral)
-
Manufacturer: CLOVIS ONCOLOGY INC
Approval date: December 19, 2016
Strength(s): EQ 200MG BASE [RLD], EQ 300MG BASE [RLD] -
Manufacturer: CLOVIS ONCOLOGY INC
Approval date: May 1, 2017
Strength(s): EQ 250MG BASE [RLD]
Has a generic version of Rubraca been approved?
No. There is currently no therapeutically equivalent version of Rubraca available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rubraca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
High dosage strength tablets of rucaparib
Patent 10,130,636
Issued: November 20, 2018
Assignee(s): Clovis Oncology, Inc.A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.
Patent expiration dates:
- August 17, 2035✓
- August 17, 2035✓
- August 17, 2035✓
- August 17, 2035✓
- August 17, 2035
-
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Patent 10,278,974
Issued: May 7, 2019
Assignee(s): Pfizer Inc.The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Patent expiration dates:
- February 10, 2031✓
- February 10, 2031
-
Tricyclic inhibitors of poly(ADP-ribose) polymerases
Patent 6,495,541
Issued: December 17, 2002
Inventor(s): Stephen Evan; Webber & Stacie S.; Canan-Koch & Jayashree; Tikhe & Lars Henrik; Thoresen
Assignee(s): Agouron Pharmaceuticals, Inc.Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. As cancer therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
Patent expiration dates:
- November 22, 2023✓✓
- November 22, 2023
-
Therapeutic compounds
Patent 7,351,701
Issued: April 1, 2008
Inventor(s): Helleday; Thomas & Curtin; Nicola
Assignee(s): Cancer Research Technology Limited Pfizer, Inc.The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Patent expiration dates:
- July 23, 2024✓
- July 23, 2024✓
- July 23, 2024✓
- July 23, 2024
-
Therapeutic compounds
Patent 7,531,530
Issued: May 12, 2009
Inventor(s): Helleday; Thomas & Curtin; Nicola
Assignee(s): Cancer Research Technology Limited PfizerThe invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Patent expiration dates:
- July 23, 2024✓
- July 23, 2024✓
- July 23, 2024✓
- July 23, 2024
-
DNA damage repair inhibitors for the treatment of cancer
Patent 8,071,579
Issued: December 6, 2011
Inventor(s): Ashworth; Alan & Jackson; Stephen & Martin; Niall & Smith; Graeme
Assignee(s): The Institute of Cancer Research: Royal Cancer Hospital Kudos Pharmaceuticals LimitedThe present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027
-
DNA damage repair inhibitors for treatment of cancer
Patent 8,143,241
Issued: March 27, 2012
Inventor(s): Ashworth; Alan & Jackson; Stephen & Martin; Niall & Smith; Graeme & O'Connor; Mark
Assignee(s): Kudos Pharmaceuticals Limited The Institute of Cancer ResearchThe present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027
-
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
Patent 8,754,072
Issued: June 17, 2014
Assignee(s): Pfizer Inc.The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Patent expiration dates:
- February 10, 2031✓✓
- February 10, 2031
-
Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Patent 8,859,562
Issued: October 14, 2014
Assignee(s): The University of SheffieldThe present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
Patent expiration dates:
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031
-
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Patent 9,045,487
Issued: June 2, 2015
Assignee(s): PFIZER INC.The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Patent expiration dates:
- February 10, 2031✓✓
- February 10, 2031
-
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Patent 9,861,638
Issued: January 9, 2018
Assignee(s): PFIZER INC.The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Patent expiration dates:
- February 10, 2031✓
- February 10, 2031✓
- February 10, 2031
-
High dosage strength tablets of rucaparib
Patent 9,987,285
Issued: June 5, 2018
Assignee(s): CLOVIS ONCOLOGY, INC.A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.
Patent expiration dates:
- August 17, 2035✓
- August 17, 2035
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 6, 2021 - FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- December 19, 2021 - NEW CHEMICAL ENTITY
- May 15, 2023 - TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
- December 19, 2023 -
- April 6, 2025 -
More about Rubraca (rucaparib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: PARP inhibitors
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
